Clinical trials: Advanced Ovarian Carcinoma
Breast Cancer, Colorectal Cancer
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00027534
- Testing
- TRICOM-CEA(6D)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michael Morse, MD
Advanced Ovarian Cancer
Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
To compare dose-dense chemotherapy with intraperitoneal chemotherapy in patients with advanced stage ovarian cancer.
- Trial name
- NCT04135521
- Testing
- Intraperitoneal chemotherapy
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Far Eastern Memorial Hospital
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Solid Tumor
SMP-3124LP in Adults With Advanced Solid Tumors
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
- Trial name
- NCT06526819
- Testing
- SMP3124LP
- Where
- 13 sites in United States, Japan
- Volunteers
- 120 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
The purpose of this study is to determine the recommended dose of I-131-CLR1404, a radiolabeled therapy compound, for treating subjects with cancer that does not respond to treatment or has returned.
- Trial name
- NCT01495663
- Testing
- I-131-CLR1404
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cellectar Biosciences, Inc.
Metastatic Cancer, Metastatic Breast Cancer
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer.
- Conditions
- Metastatic Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Metastatic Gastric Cancer
- Trial name
- CHANCES (NCT05143970)
- Testing
- IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Institut Paoli-Calmettes
Solid Tumors
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
- Trial name
- NCT06386146
- Testing
- JAB-30355
- Where
- 15 sites in United States, China
- Volunteers
- 144 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Ovarian Cancer
Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
The purpose of this study is to evaluate INCB123667 in Combination With Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Participants With Advanced Epithelial Ovarian, Fallopian Tube, or Primary…
- Trial name
- MAESTRA 3 (NCT07797283)
- Testing
- INCB123667, Bevacizumab
- Volunteers
- 590 people
- Sponsor
- Incyte Corporation
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Advanced Breast Carcinoma, Advanced Ovarian Carcinoma
Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
This is a two-part Phase 1b, open-label study of ONT 10 administered in combination with varlilumab. Two different doses of varlilumab will be studied in combination with the single agent recommended dose of ONT 10.
- Trial name
- NCT02270372
- Testing
- ONT-10, Varlilumab combination
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cascadian Therapeutics Inc.
Breast Cancer, Colorectal Cancer
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of solid tumors by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00620295
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Neoplasms
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer.
- Trial name
- NCT02655016
- Testing
- Niraparib
- Where
- 116 sites in United States, Belgium and 12 more
- Volunteers
- 733 people
- Sponsor
- Tesaro, Inc.
Ovarian Cancer
A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer
This is non randomised, open label, dose finding, efficacy and safety study, enrolling patients with advanced (stage III and IV) ovarian cancer It will be conducted in two successive phases. Phase II has a two-step design
- Trial name
- NCT00831636
- Testing
- CP-4055
- Where
- 5 sites in Belgium, Italy
- Volunteers
- 28 people
- Sponsor
- Clavis Pharma
Advanced Solid Tumor, Gynecologic Cancer
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of…
- Trial name
- NCT04042116
- Testing
- Lucitanib, Nivolumab
- Where
- 27 sites in United States, Austria and 4 more
- Volunteers
- 227 people
- Sponsor
- Clovis Oncology, Inc.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia
The goal of this non-randomized prospective study is to use 18F-EF5-PET/CT imaging to identify and locate intraabdominal hypoxic ovarian cancer lesions.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma, Hypoxia
- Trial name
- OVANOX (NCT04001023)
- Testing
- Imaging with 18F-EF5 PET/CT
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Turku University Hospital
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab)…
- Trial name
- NCT01708161
- Testing
- BYL719, AMG 479
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Neoplasms
Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma
Since the mortality rates for patients with advanced ovarian carinoma are high, the most likely way to improve progression free and overall survival is with maximal "upfront" therapy (Morrow \& Curtin, 1998).
- Trial name
- NCT00976183
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gynecologic Oncology Associates
Thrombocytopenia
The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients
Niraparib brings a better prognosis to those with advanced ovarian cancer and has been approved by the Food and Drug Administration（FDA ）and National Medical Products Administration（NMPA）as one of the maintenance therapies for…
- Trial name
- NCT06036966
- Testing
- Hetrombopag
- Volunteers
- 34 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.